NCT02355613
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 3
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 85 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patient must have 1 – 4 brain metastases
Exclusions: Patients with prior whole brain radiotherapy (WBRT)
https://ClinicalTrials.gov/show/NCT02355613